Bafna Pharmaceuticals Limited
NSE: BAFNAPH
NSE
149.68
2.93 (2.00%)
Prev Close
146.75
Open Price
149.68
Volume
6,239
Today Low / High
149.65 / 149.68
52 WK Low / High
69 / 202.06
Range
142 - 157
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 149.68, with a change of 2.93 (1.99659%). The expected target range on the NSE is between 142 - 157. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
19 Dec
149.68
0.00%
18 Dec
146.84
-0.06%
17 Dec
143.97
0.00%
16 Dec
141.10
0.04%
15 Dec
142.71
0.48%
12 Dec
143.42
1.51%
11 Dec
142.74
0.00%
10 Dec
137.48
1.80%
09 Dec
137.48
0.00%
08 Dec
142.20
-1.35%
05 Dec
142.30
0.60%
04 Dec
145.19
0.00%
03 Dec
148.16
0.00%
02 Dec
157.36
-3.92%
01 Dec
148.60
3.82%
30 Nov
154.28
0.00%
28 Nov
151.26
0.00%
27 Nov
154.35
0.00%
26 Nov
157.50
0.00%
25 Nov
160.72
0.00%
24 Nov
160.46
2.21%
Bafna Pharmaceuticals Limited Graph
Bafna Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Bafna Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 149.68, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 149.68 | 151.18 | 136.06 - 166.29 |
| 152.67 | 122.14 - 183.21 | ||
| 154.17 | 107.92 - 200.42 | ||
| Bearish Scenario | 149.68 | 148.18 | 133.36 - 163.00 |
| 146.69 | 117.35 - 176.02 | ||
| 145.19 | 101.63 - 188.75 |
Overview of Bafna Pharmaceuticals Limited
ISIN
INE878I01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
7,999
Market Cap
3,540,880,223
Last Dividend
0
Official Website
IPO Date
2012-11-12
DCF Diff
171.02
DCF
-62
Financial Ratios Every Investor Needs
Stock Dividend of BAFNAPH
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2013-09-19 | September 19, 13 | 0.6 | 0.06 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 145.86 Cr | 128.98 Cr | 16.88 Cr | 0.1157 | 2.19 Cr | 2.73 Cr | 6.29 Cr | 4.15 Cr | 1.76 | 11.77 Cr | 0.0285 |
| 2024-03-31 | 152.47 Cr | 107.25 Cr | 45.22 Cr | 0.2966 | 1.54 Cr | 19.31 Cr | 23.77 Cr | 7.35 Cr | 3.11 | 14.63 Cr | 0.0482 |
| 2023-03-31 | 115.35 Cr | 76.59 Cr | 38.76 Cr | 0.3360 | 0.72 Cr | 1.48 Cr | 10.39 Cr | 11.34 Cr | 4.79 | 18.99 Cr | 0.0983 |
| 2022-03-31 | 85.14 Cr | 51.54 Cr | 33.86 Cr | 0.3977 | 1.47 Cr | 1.99 Cr | 6.50 Cr | 5.22 Cr | 2.21 | 11.23 Cr | 0.0613 |
| 2021-03-31 | 71.22 Cr | 45.46 Cr | 25.76 Cr | 0.3617 | 1.36 Cr | 0.72 Cr | 5.85 Cr | 5.83 Cr | 2.46 | 10.39 Cr | 0.0818 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3.43 Cr | 153.08 Cr | 68.27 Cr | 84.8065 Cr | 28.20 Cr | 24.77 Cr | 28.09 Cr | 66.09 Cr | 0.00 Cr | 0.00 Cr | 0.81 Cr | 51.8517 Cr |
| 2024-03-31 | 1.40 Cr | 147.68 Cr | 66.84 Cr | 80.8390 Cr | 24.39 Cr | 22.99 Cr | 29.64 Cr | 50.71 Cr | 0.00 Cr | 1.61 Cr | 0.00 Cr | 54.0830 Cr |
| 2023-03-31 | 7.81 Cr | 129.58 Cr | 56.13 Cr | 73.4546 Cr | 22.92 Cr | 15.11 Cr | 22.22 Cr | 40.23 Cr | 0.00 Cr | 1.22 Cr | 0.00 Cr | 46.4763 Cr |
| 2022-03-31 | 0.02 Cr | 90.14 Cr | 28.18 Cr | 61.9637 Cr | 11.06 Cr | 11.04 Cr | 20.28 Cr | 38.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 22.0127 Cr |
| 2021-03-31 | 1.80 Cr | 86.47 Cr | 29.69 Cr | 56.7711 Cr | 13.00 Cr | 11.20 Cr | 15.44 Cr | 36.80 Cr | 0.89 Cr | 0.00 Cr | 0.00 Cr | 24.3088 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 19.5290 Cr | -21.3016 Cr | 3.8093 Cr | -2.3307 Cr | 2.0367 Cr | 3.4327 Cr | -21.8597 Cr | 4.1525 Cr | 3.8093 Cr | 0.0000 Cr | 1.1802 Cr |
| 2024-03-31 | 9.4848 Cr | -15.0536 Cr | -0.8454 Cr | -6.0934 Cr | -6.4134 Cr | 1.3960 Cr | -15.5782 Cr | 7.3479 Cr | 1.4654 Cr | 0.0000 Cr | -7.4231 Cr |
| 2023-03-31 | 4.9525 Cr | -7.4932 Cr | 10.1771 Cr | -3.2661 Cr | 7.6364 Cr | 7.8094 Cr | -6.7187 Cr | 11.7691 Cr | 11.8645 Cr | 0.0000 Cr | -1.9391 Cr |
| 2022-03-31 | 9.7283 Cr | -6.5442 Cr | -4.8148 Cr | 2.1871 Cr | -1.6307 Cr | 0.1730 Cr | -7.5412 Cr | 5.2163 Cr | -4.7266 Cr | 0.0000 Cr | -4.8372 Cr |
| 2021-03-31 | -13.6089 Cr | -5.3454 Cr | 12.2798 Cr | -19.7036 Cr | -6.6764 Cr | 1.8037 Cr | -6.0947 Cr | 5.8267 Cr | 12.3684 Cr | 0.0000 Cr | -4.0309 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 35.47 Cr | 23.06 Cr | 12.41 Cr | 0.3498 | 2.81 Cr | 3.12 Cr | 1.32 | 5.46 Cr | 0.0881 |
| 2025-06-30 | 34.62 Cr | 22.42 Cr | 12.21 Cr | 0.3525 | 3.70 Cr | 3.39 Cr | 1.43 | 5.66 Cr | 0.0979 |
| 2025-03-31 | 39.06 Cr | 32.38 Cr | 6.68 Cr | 0.1710 | 2.90 Cr | 1.31 Cr | 0.55 | 2.35 Cr | 0.0336 |
| 2024-12-31 | 33.19 Cr | 23.63 Cr | 9.56 Cr | 0.2881 | 1.41 Cr | 0.95 Cr | 0.40 | 3.24 Cr | 0.0286 |
| 2024-09-30 | 40.32 Cr | 27.76 Cr | 12.57 Cr | 0.3117 | 2.22 Cr | 2.62 Cr | 1.11 | 4.82 Cr | 0.0649 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 0.25 Cr | 1.71 Cr | 1.97 Cr | 32.67 Cr | 31.00 Cr | 80.07 Cr | 79.67 Cr | 160.68 Cr | 69.45 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 3.43 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -84.81 Cr |
| 2025-03-31 | 3.43 Cr | 0.00 Cr | 3.43 Cr | 40.20 Cr | 28.09 Cr | 84.73 Cr | 66.09 Cr | 153.08 Cr | 68.27 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -82.75 Cr |
| 2024-09-30 | 1.31 Cr | 0.01 Cr | 1.32 Cr | 0.07 Cr | 27.47 Cr | 74.61 Cr | 55.53 Cr | 134.16 Cr | 51.41 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 3.39 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 1.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 0.95 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 2.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -0.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-08-26 | August 26, 19 | 1:10 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,745.50 | ₹4,188,039,190,135.00 | ₹2,768,986.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,460.00 | ₹1,714,927,026,800.00 | ₹785,205.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,792.10 | ₹1,283,418,953,024.00 | ₹150,394.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,280.10 | ₹1,065,699,283,253.00 | ₹1,209,487.00 |
| Lupin Limited | LUPIN | ₹2,124.00 | ₹970,240,663,944.00 | ₹595,995.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹920.00 | ₹925,735,270,800.00 | ₹799,834.00 |
| Mankind Pharma Limited | MANKIND | ₹2,177.00 | ₹898,676,641,744.00 | ₹491,349.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,225.00 | ₹711,481,988,175.00 | ₹1,396,499.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,582.50 | ₹667,471,612,500.00 | ₹51,668.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,047.90 | ₹565,715,712,278.00 | ₹2,844,049.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,992.00 | ₹562,144,011,528.00 | ₹527,847.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,430.50 | ₹362,923,883,849.00 | ₹169,772.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,641.20 | ₹329,979,970,109.00 | ₹110,006.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,808.00 | ₹283,224,928,448.00 | ₹90,461.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,385.00 | ₹262,547,317,250.00 | ₹43,615.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,412.00 | ₹229,438,942,628.00 | ₹3,918,116.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,050.50 | ₹226,262,500,000.00 | ₹5,946.00 |
| Eris Lifesciences Limited | ERIS | ₹1,568.00 | ₹213,588,085,088.00 | ₹36,657.00 |
| Cohance Lifesciences Limited | COHANCE | ₹536.85 | ₹205,381,169,109.00 | ₹740,594.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,970.00 | ₹204,893,327,330.00 | ₹80,404.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,079.00 | ₹171,019,811,365.00 | ₹385,360.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹860.00 | ₹169,044,286,640.00 | ₹65,161.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹917.40 | ₹164,315,394,738.00 | ₹828,324.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,930.00 | ₹146,702,573,280.00 | ₹23,454.00 |
| Granules India Limited | GRANULES | ₹583.30 | ₹141,548,662,043.00 | ₹2,093,530.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹896.20 | ₹109,947,024,078.00 | ₹28,703.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,700.00 | ₹94,616,477,400.00 | ₹8,085.00 |
| Strides Pharma Science Limited | STAR | ₹931.00 | ₹85,812,796,734.00 | ₹1,135,457.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹746.00 | ₹67,622,881,324.00 | ₹138,130.00 |
| FDC Limited | FDC | ₹409.65 | ₹66,695,150,911.00 | ₹44,583.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹428.00 | ₹65,527,680,824.00 | ₹79,062.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹324.80 | ₹63,524,973,837.00 | ₹217,367.00 |
| Sequent Scientific Limited | SEQUENT | ₹210.40 | ₹52,562,931,518.00 | ₹611,341.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹144.71 | ₹46,961,518,999.00 | ₹5,394,459.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹405.00 | ₹44,130,932,325.00 | ₹842,535.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹789.00 | ₹40,017,373,845.00 | ₹47,690.00 |
| Innova Captab Limited | INNOVACAP | ₹689.90 | ₹39,479,478,517.00 | ₹23,459.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,340.90 | ₹38,716,180,214.00 | ₹4,275.00 |
| Suven Life Sciences Limited | SUVEN | ₹171.70 | ₹37,843,712,776.00 | ₹168,475.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹351.45 | ₹35,244,286,734.00 | ₹19,683.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹385.00 | ₹35,138,950,000.00 | ₹204,912.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹454.90 | ₹32,027,575,675.00 | ₹12,333.00 |
| Hikal Limited | HIKAL | ₹235.35 | ₹29,018,831,513.00 | ₹187,626.00 |
Key Executives
Company Secretary & Compliance Officer
A. Mohanachandran
Gender: male
Year Born:
Chief Executive Officer
Bansilal Mahaveer Chand Bafna
Gender: male
Year Born: 1961
Chief Financial Officer
Melagiri Sridhar
Gender: male
Year Born: 1968
Whole-Time Director of Quality & Whole-Time Director
Vinayak Dinesh Dendukuri
Gender: male
Year Born: 1987
Whole-Time Director
Shanmugam Hemalatha
Gender: female
Year Born: 1975
FAQs about Bafna Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Bansilal Mahaveer Chand Bafna.
What is the current market price of the stock?
The current price is ₹149.68.
What is the 52-week price range?
The range is ₹69-202.06.
What is the market capitalization of the company?
The market capitalization is ₹354.09 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 40.39.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Bafna Pharmaceuticals Limited (ISIN: INE878I01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹354.09 crores and an average daily volume of 7,999 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.